Literature DB >> 7478598

The Epstein-Barr virus encoded cytokine viral interleukin-10 enhances transformation of human B lymphocytes.

A D Stuart1, J P Stewart, J R Arrand, M Mackett.   

Abstract

In vitro infection of human B lymphocytes with Epstein-Barr virus (EBV) results in their growth transformation and establishment of immortalised lymphoblastoid cell lines. The virus was recently found to encode a homologue of the pleitropic cytokine interleukin-10 (IL-10), which has wide ranging effects on the immune system. We have investigated the effect of this virally encoded growth factor on the ability of EBV to immortalize B lymphocytes from tonsils and from adult and neonatal blood. Recombinant viral interleukin-10 (vIL-10) was found to increase dramatically the growth transformation of B cells from all three populations infected with either the highly transforming type 1 strain B95-8 or the less efficient type 2 strain BL16. This striking enhancement of transforming ability in the presence of viral IL-10 may be in part due to increased viability of the B cells during infection and decreased levels of interferon-gamma, a cytokine known to inhibit EBV transformation. Thus viral IL-10 influences a number of cell types of the immune system to allow the enhanced outgrowth of EBV transformed cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7478598

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  21 in total

1.  Epstein-Barr virus BARF1 protein is dispensable for B-cell transformation and inhibits alpha interferon secretion from mononuclear cells.

Authors:  J I Cohen; K Lekstrom
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

Review 2.  Cytokine homologs of human gammaherpesviruses.

Authors:  Sang-Hoon Sin; Dirk P Dittmer
Journal:  J Interferon Cytokine Res       Date:  2011-12-05       Impact factor: 2.607

3.  ICAM-1, soluble-CD23, and interleukin-10 concentrations in serum in renal-transplant recipients with Epstein-Barr virus reactivation.

Authors:  M W Hornef; G Bein; D Wilhelm; L Fricke; H Kirchner
Journal:  Clin Diagn Lab Immunol       Date:  1997-09

4.  Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model.

Authors:  Gregory K Hong; Margaret L Gulley; Wen-Hai Feng; Henri-Jacques Delecluse; Elizabeth Holley-Guthrie; Shannon C Kenney
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

5.  Isolation of intertypic recombinants of Epstein-Barr virus from T-cell-immunocompromised individuals.

Authors:  Q Y Yao; R J Tierney; D Croom-Carter; G M Cooper; C J Ellis; M Rowe; A B Rickinson
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

6.  Initiation of lytic DNA replication in Epstein-Barr virus: search for a common family mechanism.

Authors:  Andrew J Rennekamp; Paul M Lieberman
Journal:  Future Virol       Date:  2010-01       Impact factor: 1.831

7.  The BHLF1 Locus of Epstein-Barr Virus Contributes to Viral Latency and B-Cell Immortalization.

Authors:  Kristen D Yetming; Lena N Lupey-Green; Sergei Biryukov; David J Hughes; Elessa M Marendy; Jj L Miranda; Jeffery T Sample
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

Review 8.  Manipulation of the host cell membrane by human γ-herpesviruses EBV and KSHV for pathogenesis.

Authors:  Fang Wei; Qing Zhu; Ling Ding; Qing Liang; Qiliang Cai
Journal:  Virol Sin       Date:  2016-09-12       Impact factor: 4.327

9.  Dithiocarbamates and viral IL-10 collaborate in the immortalization and evasion of immune response in EBV-infected human B lymphocytes.

Authors:  Richard D Irons; Anh Tuan Le
Journal:  Chem Biol Interact       Date:  2007-11-22       Impact factor: 5.192

Review 10.  Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD.

Authors:  G Tosato; J Teruya-Feldstein; J Setsuda; S E Pike; K D Jones; E S Jaffe
Journal:  Springer Semin Immunopathol       Date:  1998
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.